Advertisement
Canada markets close in 3 hours 17 minutes

  • S&P/TSX

    22,331.68
    -44.15 (-0.20%)
     

  • S&P 500

    5,215.91
    +1.83 (+0.04%)
     

  • DOW

    39,486.87
    +99.11 (+0.25%)
     

  • CAD/USD

    0.7319
    +0.0008 (+0.11%)
     

  • CRUDE OIL

    78.50
    -0.76 (-0.96%)
     

  • Bitcoin CAD

    83,191.28
    -2,124.63 (-2.49%)
     

  • CMC Crypto 200

    1,264.25
    -93.75 (-6.90%)
     

  • GOLD FUTURES

    2,370.80
    +30.50 (+1.30%)
     

  • RUSSELL 2000

    2,057.50
    -16.13 (-0.78%)
     

  • 10-Yr Bond

    4.5080
    +0.0590 (+1.33%)
     

  • NASDAQ

    16,312.27
    -34.00 (-0.21%)
     

  • VOLATILITY

    12.77
    +0.08 (+0.63%)
     

  • FTSE

    8,433.76
    +52.41 (+0.63%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • CAD/EUR

    0.6787
    +0.0009 (+0.13%)
     
MARKETS LIVE BLOG:

STOCKS RISE AS DOW EYES GAIN FOR 8TH STRAIGHT SESSION

U.S. consumer sentiment tumbles in May as inflation, interest rate worries take hold

Krystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference

Krystal Biotech, Inc.
·1 min read
Krystal Biotech, Inc.
Krystal Biotech, Inc.

PITTSBURGH, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the Evercore ISI 5th Annual HealthCONx Conference, which is taking place virtually from November 29-December 1.

Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat during the conference and host investor meetings on November 30.

A webcast of the presentation will be available here at 10:30 am ET on Wednesday, November 30 and will be posted on the Investor section of the Company’s website.

ADVERTISEMENT

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The Company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. Headquartered in Pittsburgh, Pennsylvania, the Company is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and Twitter.

CONTACT:

Investors and Media                                                                
Meg Dodge                                                      
Krystal Biotech                                                    
mdodge@krystalbio.com                                             
Source: Krystal Biotech, Inc.